MIGUEL
MINGUEZ PEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
University of Amsterdam
Ámsterdam, HolandaUniversity of Amsterdam-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2022
-
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 4, pp. 294-306